CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Resistant to Bevacizumab and Ranibizumab.
Jong Ha Kim, Nam Chun Cho, Woo Jin Kim
J Korean Ophthalmol Soc. 2015;56(9):1359-1364.   Published online September 15, 2015
DOI: https://doi.org/10.3341/jkos.2015.56.9.1359

Excel Download

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Resistant to Bevacizumab and Ranibizumab
Journal of the Korean Ophthalmological Society. 2015;56(9):1359   Crossref logo
Link1 Link2 Link3

Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age-related macular degeneration patients
Acta Ophthalmologica. 2016;94:   Crossref logo
Link1 Link2

A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration
International Ophthalmology. 2016;37(5):1205-1214   Crossref logo
Link1 Link2 Link3

Rapid response to intravitreal aflibercept in neovascular age-related macular degeneration after development of tachyphylaxis to bevacizumab and ranibizumab
Taiwan Journal of Ophthalmology. 2014;4(1):40-44   Crossref logo
Link1 Link2

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
Journal of Ophthalmology. 2014;2014:1-6   Crossref logo
Link1 Link2 Link3

Response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory ranibizumab
Acta Ophthalmologica. 2013;91:0-0   Crossref logo
Link1 Link2

Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept
Journal Français d'Ophtalmologie. 2017;40(10):832-838   Crossref logo
Link1 Link2

Cost Utility Analysis Of Aflibercept, Ranibizumab, And Bevacizumab For The Treatment Of Neovascular Age-Related Macular Degeneration
Value in Health. 2014;17(3):A287   Crossref logo
Link1 Link2

Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab
Ophthalmology. 2015;122(9):1802-1810   Crossref logo
Link1 Link2

Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden
European Journal of Ophthalmology. 2019;31(1):144-148   Crossref logo
Link1 Link2 Link3